Treatment
Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease
X. Chen1, W. Jiang2, Q. Jin3, S. Lin4, L. Zhang5, Q. Peng6, H. Sun7, Y. Wang8, X. Lu9, A. Song10, G. Wang11, Y. Ge12
- Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
- Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.
- Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
- Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.
- Department of Rheumatology, China-Japan Friendship Hospital, Beijing, and Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China.
- Department of Radiology, China-Japan Friendship Hospital, Beijing, China.
- Department of Radiology, China-Japan Friendship Hospital, Beijing, China.
- Department of Rheumatology, China-Japan Friendship Hospital, Beijing, and Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China.
- Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
- Peking University China-Japan Friendship School of Clinical Medicine, Beijing; Department of Rheumatology, China-Japan Friendship Hospital, Beijing; and Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China.
- Department of Rheumatology, China-Japan Friendship Hospital, Beijing, and Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China. gyp2016@163.com
CER16953
2024 Vol.42, N°2
PI 0386, PF 0393
Treatment
Free to view
(click on article PDF icon to read the article)
PMID: 38153137 [PubMed]
Received: 28/06/2023
Accepted : 24/10/2023
In Press: 27/12/2023
Published: 14/03/2024
Abstract
OBJECTIVES:
To determine the efficacy and safety of nintedanib in patients with anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis-associated interstitial lung disease (anti-MDA5+ DM-ILD).
METHODS:
The study was a retrospective cohort design that evaluated patients with anti-MDA5+ DM who either received or did not receive nintedanib. Clinical symptoms, laboratory tests, and survival were compared in the two groups using a propensity score-matched analysis. The primary endpoint was mortality, while adverse events were recorded descriptively.
RESULTS:
After propensity score matching, 14 patients who received nintedanib (nintedanib+ group) and matched 56 patients who did not receive nintedanib (nintedanib- group) were enrolled. Compared with the nintedanib- group, the nintedanib+ group had a lower incidence of heliotrope and arthritis, higher lymphocyte counts, lower serum ferritin levels, and greater 12-month survival (all p<0.005). Although lung function, HRCT score, and lung VAS were not statistically different between the two groups, the longitudinal study showed significant improvement in HRCT scores (p=0.028) and pulmonary VAS (p=0.019) in the nintedanib+ group. Adverse events occurred in 28.6% of patients, with the most common adverse event with nintedanib being diarrhoea.
CONCLUSIONS:
Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM. Diarrhoea was the most common adverse event associated with nintedanib, although the drug was well tolerated by most patients.
